Xvivo Perfusion AB's Total Assets for the quarter that ended in Mar. 2024 was kr2,253.7 Mil.
Warning Sign:
If a company builds assets at 36.4% a year, faster than its revenue growth rate of 22.3% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Xvivo Perfusion AB's average Total Assets Growth Rate was 13.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 27.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 36.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 31.50% per year.
During the past 12 years, Xvivo Perfusion AB's highest 3-Year average Total Assets Growth Rate was 46.20%. The lowest was 13.30%. And the median was 32.30%.
The historical data trend for Xvivo Perfusion AB's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Xvivo Perfusion AB's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (OSTO:XVIVO) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Xvivo Perfusion AB's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Xvivo Perfusion AB Total Assets Related Terms
Thank you for viewing the detailed overview of Xvivo Perfusion AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Xvivo Perfusion AB (OSTO:XVIVO) Business Description
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:XVIVO has been successfully added to your 